All In Biotech

Drug Trial Radar · NCT01602952

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)

Last checked: Nov 19, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Jul 2008

Primary completion

Oct 2012

Study completion Jul 13, 2018

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
May 21, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated phases. Phase 1 1\. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously. Phase 2 1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases. 2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.

Conditions

  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Philadelphia Chromosome
  • Hematologic Diseases

Interventions

  • RadotinibDrug

    50mg, 100mg or 200mg Capsule BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the Maximum Tolerated Dose(Phase 1)Time frame: 12 month
  2. Rate of Complete hematologic response(CHR)(Phase 2)Time frame: 12 months

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Local institution

    Mumbai, Maharashtra, India

  • Local institution

    Mumbai, Mazagaon, India

  • Local institution

    Daegu, Buk-gu, South Korea

  • Local institution

    Jeonju, Deokjin-gu, South Korea

  • Local institution

    Ulsan, Dong-gu, South Korea

  • Local institution

    Anyang-si, Dongan-gu, South Korea

  • Local institution

    Hwasun, Hwasun-eup, South Korea

  • Local institution

    Seoul, Jongro-ku, South Korea

  • Local institution

    Busan, Seo-gu, South Korea

  • Seoul St. Mary's hospital

    Seoul, Seocho-gu, South Korea

  • Local institution

    Suwon, Yeongtong-gu, South Korea

  • Local institution

    Bangkok, Phyathai, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.